CN1957984A - 一种治疗过敏性鼻炎用的囊泡及其制备方法 - Google Patents
一种治疗过敏性鼻炎用的囊泡及其制备方法 Download PDFInfo
- Publication number
- CN1957984A CN1957984A CN 200610154630 CN200610154630A CN1957984A CN 1957984 A CN1957984 A CN 1957984A CN 200610154630 CN200610154630 CN 200610154630 CN 200610154630 A CN200610154630 A CN 200610154630A CN 1957984 A CN1957984 A CN 1957984A
- Authority
- CN
- China
- Prior art keywords
- allergic rhinitis
- composition proportion
- vesicle
- preparation
- ctab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039085 Rhinitis allergic Diseases 0.000 title claims abstract description 16
- 201000010105 allergic rhinitis Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000002775 capsule Substances 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 16
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims abstract description 9
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract description 8
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract description 8
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000005642 Oleic acid Substances 0.000 claims abstract description 8
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 8
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 8
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract description 8
- 239000012153 distilled water Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 235000004347 Perilla Nutrition 0.000 claims description 10
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 7
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 7
- 239000008347 soybean phospholipid Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 6
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 6
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 6
- 229960003415 propylparaben Drugs 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 244000124853 Perilla frutescens Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 15
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 abstract 1
- 239000001335 perilla frutescens leaf extract Substances 0.000 abstract 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 210000004877 mucosa Anatomy 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- 210000002850 nasal mucosa Anatomy 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000003266 anti-allergic effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010028748 Nasal obstruction Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000002590 anti-leukotriene effect Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000004777 chromones Chemical class 0.000 description 2
- 239000000850 decongestant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940073610 elocon Drugs 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 235000004348 Perilla frutescens Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000026062 Tissue disease Diseases 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- 235000009108 Urtica dioica Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229910052567 struvite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗过敏性鼻炎用的囊泡及其制备方法,该囊泡的成分配比为:紫苏子油0.4g,大豆磷脂7g,胆固醇2g,丙二醇10g,吐温80 4g,CTAB1g,尼泊金甲酯0.6g,尼泊金丙酯0.2g,油酸5g,单硬脂酸甘油酯1g,蒸馏水加至100g。同现有技术比较,本发明的优点是:制备工艺简单、稳定性好、患者依从性高,治疗过敏性鼻炎起效快、且无任何副作用,来源广泛,药食同源,携带方便,对常年或季节性变应性鼻炎疗效优于现有的同类药物,14天治愈率可达91.2%。
Description
技术领域
本发明涉及一种含有来源于植物材料的医用配制品,特别涉及一种治疗过敏性鼻炎用的囊泡及其制备方法。
背景技术
过敏性鼻炎是由IgE为介导的鼻黏膜组织的慢性炎症性疾病。在病变过程中,多种炎症性细胞参与以及由其释放的各种介质、细胞因子和位于鼻黏膜组织中的一些炎症活性物质,都对炎症的发生、发展以及鼻部症状的出现起重要的作用。目前治疗过敏性鼻炎的常用药物有抗组织胺药,皮质类固醇类药,色酮类药,减充血剂药和抗白三烯药等。其中抗组织胺药起效快,但对鼻充血效果差;皮质类固醇类药可抑制鼻黏膜的炎症反应,但起效慢,且对有些人群不适用;色酮类药只适合于预防性治疗;减充血剂药可缓解鼻塞症状,但对其它症状无效,长期应用易产生药物性鼻炎;抗白三烯药耐受性好,但目前只有口服制剂。临床上仍在寻求一种起效快、疗效好且无副作用的治疗过敏性鼻炎用的药物。
被中国药典所收载的紫苏子,具有抗炎、抗过敏作用,现代药理证明:紫苏子含有两大类抗过敏、抗炎症物质,即脂肪酸类成分和多元酚类成分,它们均属于过敏介质拮抗剂类。紫苏子油是用唇形科植物紫苏(Perillafrutescens[L]Britt)的干燥成熟果实紫苏子压榨而得的脂肪油,紫苏子油含有较高的α-亚麻酸(可高达70%以上)成分,在体内代谢过程中,通过竞争酶系统,能抑制亚油酸向花生四烯酸转化,从而降低体内花生四烯酸水平,减少前列腺素等过敏介质的产生。通过对T-细胞功能的调节,可抑制Th2细胞因子分泌功能,同时它还具有抑制白三烯、血管活化因子和组胺的作用,具有较强的抗过敏作用,临床上尤其对物理性光辐射与温差的变化、化学物的刺激、虾蟹类无脊椎动物蛋白类食物引发的过敏性荨蔴症、变应性鼻炎、咽炎、哮喘性咳嗽均有良效。对鼻炎自觉症状如喷嚏、流涕和鼻塞有很好的改善作用。
现代医学研究已证实,大多数传染性疾病其病原体是通过黏膜表面(如皮肤、呼吸道黏膜、胃肠道黏膜、生殖道黏膜等)侵入机体的,机体约有80%的感染首先发生在黏膜,可见黏膜免疫的重要性,故有学者提出了“黏膜免疫系统”的概念。现阶段,临床上使用的疫苗均以注射为主要途径。由于常规的注射疫苗只能产生全身性的体液免疫应答,而对病原体入侵部位则无法产生相应的局部免疫应答和长久的免疫记忆力。可以通过粘膜产生免疫的给药途径有:口服给药、鼻粘膜给药、肺部给药、直肠给药和阴道给药等,其中鼻粘膜免疫被证明为最有效和方便的途径。
鼻腔具有约150cm2丰富的黏膜,黏膜上有系列绒毛和上皮细胞,绒毛使鼻黏膜吸收面积增加,黏膜下大量的毛细血管网,使药物可以很快被吸收。鼻腔给药具有药物吸收迅速、给药后起效时间快、无首过效应、无胃肠道反应、生物利用度高等优点,药物可达到高效、速效、安全、方便的治疗效果。紫苏来源广,价廉,有广泛的药食两用的基础。所以对细胞因子拮抗剂-紫苏制剂的开发具有广阔的前景。
发明内容
本发明的目的是提供一种治疗过敏性鼻炎用的囊泡及其制备方法,其中有效剂量为紫苏子油,紫苏子油日给药剂量为0.015~0.40g;该液体制剂含有精选的免疫佐剂,增溶剂,黏膜吸收促进剂,稳定剂以及防腐剂,用于治疗过敏性鼻炎具有起效快、疗效好且无任何副作用的优点。
黏膜吸收促进剂选用大豆磷脂、胆固醇、油酸、吐温80的混合物,增溶剂选用丙二醇,稳定剂选用十六烷基三甲基溴化铵CTAB,防腐剂选用尼泊金甲酯和尼泊金乙酯中的混合物。
一种治疗过敏性鼻炎用的囊泡及其制备方法,其特征在于该囊泡的成分配比为:
紫苏子油 0.4g
大豆磷脂 7g
胆固醇 2g
丙二醇 10g
吐温80 4g
CTAB 1g
尼泊金甲酯 0.6g
尼泊金丙酯 0.2g
油酸 5g
单硬脂酸甘油酯 1g
蒸馏水 加至100g
一种治疗过敏性鼻炎用的囊泡及其制备方法,其特征在于采用下列步骤:
1)依据成分配比称取油酸、单硬脂酸甘油酯,置于容器中加热60℃,形成透明溶液;
2)往上述容器中,按成分配比加入含吐温80、CTAB、尼泊金甲酯、尼泊金丙酯、蒸馏水,经高速搅拌剪切形成乳液;
3)按成分配比称取紫苏子油,大豆磷脂,胆固醇,用丙二醇溶解后,在搅拌条件下加入上述乳液,充分振摇至分散均匀,获得乳白色的液体。
同现有技术比较,本发明的突出优点是:制备工艺简单、稳定性好、患者依从性高,治疗过敏性鼻炎起效快、且无任何副作用,来源广泛,药食同源,携带方便,对常年或季节性变应性鼻炎疗效优于现有的同类药物,7天的治愈率可达85%以上。
具体实施方式
实施例1:
一种治疗过敏性鼻炎用的囊泡及其制备方法,其特征在于该囊泡的成分配比为:紫苏子油 0.4g
大豆磷脂 7g
胆固醇 2g
丙二醇 10g
吐温80 4g
CTAB 1g
尼泊金甲酯 0.6g
尼泊金丙酯 0.2g
油酸 5g
单硬脂酸甘油酯 1g
蒸馏水 加至100g
实施例2:
一种治疗过敏性鼻炎用的囊泡及其制备方法,依据成分配比称取油酸5g、单硬脂酸甘油酯1g,置于容器中加热至60℃,形成透明溶液;往上述容器中,按成分配比加入含吐温80 4g、CTAB 1g、尼泊金甲酯0.6g、尼泊金丙酯0.2g、蒸馏水100g,经高速搅拌剪切形成乳液;按成分配比称取紫苏子油0.4g,大豆磷脂7g,胆固醇2g,用丙二醇10g溶解后,在搅拌条件下加入上述乳液,充分振摇至分散均匀,制得乳白色的液体。
Claims (2)
1.一种治疗过敏性鼻炎用的囊泡,其特征在于:该囊泡的成分配比为:
紫苏子油 0.4g
大豆磷脂 7g
胆固醇 2g
丙二醇 10g
吐温80 4g
CTAB 1g
尼泊金甲酯 0.6g
尼泊金丙酯 0.2g
油酸 5g
单硬脂酸甘油酯 1g
蒸馏水 加至100g
2.一种根据权利要求1所述囊泡的制备方法,其特征在于采用下列步骤:
1)依据成分配比称取油酸、单硬脂酸甘油酯,置于容器中加热至60℃,形成透明溶液;
2)往上述容器中,按成分配比加入含吐温80、CTAB、尼泊金甲酯、尼泊金丙酯、蒸馏水,经高速搅拌剪切形成乳液;
3)按成分配比称取紫苏子油,大豆磷脂,胆固醇,用丙二醇溶解后,在搅拌条件下加入上述乳液,充分振摇至分散均匀,获得乳白色的液体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610154630 CN1957984A (zh) | 2006-11-13 | 2006-11-13 | 一种治疗过敏性鼻炎用的囊泡及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200610154630 CN1957984A (zh) | 2006-11-13 | 2006-11-13 | 一种治疗过敏性鼻炎用的囊泡及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN1957984A true CN1957984A (zh) | 2007-05-09 |
Family
ID=38069936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200610154630 Pending CN1957984A (zh) | 2006-11-13 | 2006-11-13 | 一种治疗过敏性鼻炎用的囊泡及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1957984A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860587A (zh) * | 2014-03-27 | 2014-06-18 | 袁萍 | 一种姜黄素、蒙脱石保健组合物 |
-
2006
- 2006-11-13 CN CN 200610154630 patent/CN1957984A/zh active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103860587A (zh) * | 2014-03-27 | 2014-06-18 | 袁萍 | 一种姜黄素、蒙脱石保健组合物 |
CN103860587B (zh) * | 2014-03-27 | 2018-01-19 | 袁萍 | 一种姜黄素、蒙脱石保健组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105324114B (zh) | 虾青素抗炎增效组合 | |
KR20080016596A (ko) | 의료 장치 및 의약 제형에 유용한 점액 접착성자일로글루칸 함유 제형 | |
CN1091285A (zh) | 酯肪酸药剂 | |
CN1927160A (zh) | 漱口液及制备方法 | |
CN108210689A (zh) | 一种含有透明质酸的口腔溃疡膜剂及其制备方法 | |
CN104983844A (zh) | 具有粘膜修复功能的组合物配方及其制剂的制备过程 | |
CN105560331A (zh) | 一种用于抗皮炎湿疹的药物及其制备方法和应用 | |
CN1965893A (zh) | 一种治疗过敏性鼻炎用的液体制剂 | |
CN1698620A (zh) | 一种可过滤除菌的葫芦素乳剂及制备方法 | |
CN105168500B (zh) | 一种用于治疗小儿口腔溃疡的药物组合物及其制备方法 | |
CN1957984A (zh) | 一种治疗过敏性鼻炎用的囊泡及其制备方法 | |
CN1957927B (zh) | 三萜皂苷及其衍生物的脂微球制剂及其制备方法 | |
CN103664936A (zh) | 一类治疗创伤性脑损伤疾病的化合物及其用途 | |
CN112521389B (zh) | 用于促进伤口愈合的药物及方法 | |
CN101028490A (zh) | 一种治疗痤疮的中成药 | |
CN109419787A (zh) | 一种松香烷型二萜类化合物的用途 | |
CN1965892A (zh) | 治疗过敏性鼻炎用的液体制剂 | |
CN103520262A (zh) | 一种脂溶性妇科凝胶 | |
CN105982882B (zh) | 一种光学活性原料组合物组方治疗痔疮的外用药及制备工艺 | |
CN114177160A (zh) | 一种治疗口腔溃疡的足贴及其制备方法 | |
CN1398861A (zh) | 秦皮总香豆素的制备方法及其在制药中的应用 | |
CN105362382A (zh) | 一种治疗复发性口腔溃疡中药组合物及其应用 | |
CN1698659A (zh) | 一种口腔局部用贴片的制备及其应用 | |
CN1504191A (zh) | 葫芦素脂质体组方及其制剂 | |
CN1634118A (zh) | 含有多糖聚阴离子锌盐的抗病毒制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |